Brokerages expect that Protagonist Therapeutics Inc (NASDAQ:PTGX) will post earnings of ($0.42) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Protagonist Therapeutics’ earnings, with estimates ranging from ($0.67) to ($0.17). Protagonist Therapeutics reported earnings per share of ($0.15) during the same quarter last year, which suggests a negative year over year growth rate of 180%. The company is scheduled to announce its next quarterly earnings report on Wednesday, March 6th.
According to Zacks, analysts expect that Protagonist Therapeutics will report full year earnings of ($1.58) per share for the current financial year, with EPS estimates ranging from ($1.84) to ($1.32). For the next year, analysts anticipate that the business will post earnings of ($1.99) per share, with EPS estimates ranging from ($2.58) to ($1.40). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Protagonist Therapeutics.
Several research firms recently commented on PTGX. ValuEngine downgraded shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Zacks Investment Research raised shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 26th. Finally, Nomura started coverage on shares of Protagonist Therapeutics in a research report on Thursday, December 6th. They set a “buy” rating and a $13.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the stock. Protagonist Therapeutics currently has an average rating of “Hold” and a consensus target price of $18.20.
PTGX stock opened at $7.10 on Friday. The stock has a market capitalization of $171.72 million, a P/E ratio of -3.40 and a beta of 2.10. Protagonist Therapeutics has a 12 month low of $5.49 and a 12 month high of $23.97.
In other news, insider David Y. Liu sold 3,821 shares of Protagonist Therapeutics stock in a transaction that occurred on Wednesday, February 6th. The shares were sold at an average price of $7.74, for a total value of $29,574.54. Following the transaction, the insider now owns 37,007 shares of the company’s stock, valued at approximately $286,434.18. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Dinesh V. Ph D. Patel sold 10,909 shares of Protagonist Therapeutics stock in a transaction that occurred on Wednesday, February 6th. The stock was sold at an average price of $7.74, for a total transaction of $84,435.66. Following the completion of the transaction, the chief executive officer now directly owns 367,396 shares in the company, valued at approximately $2,843,645.04. The disclosure for this sale can be found here. 13.80% of the stock is owned by insiders.
Several institutional investors have recently modified their holdings of PTGX. Acadian Asset Management LLC boosted its stake in Protagonist Therapeutics by 2.6% in the 4th quarter. Acadian Asset Management LLC now owns 256,220 shares of the company’s stock worth $1,725,000 after purchasing an additional 6,516 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Protagonist Therapeutics by 26.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 63,269 shares of the company’s stock worth $426,000 after purchasing an additional 13,303 shares in the last quarter. Vanguard Group Inc. boosted its stake in Protagonist Therapeutics by 2.6% in the 3rd quarter. Vanguard Group Inc. now owns 530,495 shares of the company’s stock worth $5,458,000 after purchasing an additional 13,341 shares in the last quarter. Vanguard Group Inc boosted its stake in Protagonist Therapeutics by 2.6% in the 3rd quarter. Vanguard Group Inc now owns 530,495 shares of the company’s stock worth $5,458,000 after purchasing an additional 13,341 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in Protagonist Therapeutics by 2,262.7% in the 2nd quarter. Bank of America Corp DE now owns 21,217 shares of the company’s stock worth $143,000 after purchasing an additional 20,319 shares in the last quarter. 66.15% of the stock is currently owned by hedge funds and other institutional investors.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.
See Also: How to Invest in an Index Fund
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.